FMP

FMP

Enter

TEVA - Teva Pharmaceut...

photo-url-https://images.financialmodelingprep.com/symbol/TEVA.png

Teva Pharmaceutical Industries Limited

TEVA

NYSE

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

16.32 USD

-0.46 (-2.82%)

Historical Prices

From:

To:

About

ceo

Mr. Richard D. Francis

sector

Healthcare

industry

Drug Manufacturers - Specialty & Generic

exchange

NYSE

Description

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treat...

CIK

0000818686

ISIN

US8816242098

CUSIP

881624209

Address

124 Dvora Hanevi'a Street

Phone

972 3 914 8213

Country

IL

Employee

33,892

IPO Date

Feb 16, 1982

Financial Statement

Earnings

TEVA Financial Summary

CIK

0000818686

Exchange

NYSE

Industry

Drug Manufacturers -...

Sector

Healthcare

CUSIP

881624209

ISIN

US8816242098

Country

IL

Price

16.32

Beta

0.71

Volume Avg.

12.22M

Market Cap

18.7B

Shares

-

52-Week

12.51-22.8

DCF

1.7

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-11.26

P/B

-

Website

https://www.tevapharm.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest TEVA News

Danny Green

Jan 28, 2025

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Earnings Pre...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is a major player in the pharmaceutical industry, known for its generic and specialty medicines. As it prepares to release its quarterly earnings on January 29, 2025, analysts predict an earnings per share (EPS) of $0.69 and revenue of around $4.1 billion. This report will provide insights into the company's financial health and market position. Despite the anticipated earnings, Teva faces financial challenges. The company has a negative price-to-...

Seeking Alpha

Aug 14, 2024

Teva's Transformation: From Generics Leader To Branded Drug ...

Step by step, Teva's management is making progress in transforming it from a generic drugmaker into one that will play a key role in the fight against immune-related disorders. Its revenue was about $4.16 billion in the second quarter of 2024, up 7.2% year-on-year. So, in addition to the growth in sales of its generic products, there is also increased demand for innovative medications, including Austedo and Uzedy.

InvestorPlace

Aug 7, 2024

The 7 Best Under $20 Stocks to Buy in August 2024

Cheap stocks are often cheap for a reason. That bit of investing wisdom underscores the need to perform due diligence on a company and not just buy it because the stock trades at a low price.

InvestorPlace

Aug 2, 2024

What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.

Sometimes the best way to jump into an industry like biotech is to follow the popular trades. Though that may go against the common advice of avoiding hype cycles and the fear of missing out, seeing which biotech stocks are experiencing the highest 24-hour trading volumes can be a quick way to learn which catalysts are driving investors to the industry.

Seeking Alpha

Jul 31, 2024

Teva Pharmaceutical Industries Limited (TEVA) Q2 2024 Earnin...

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Richard Francis - President & CEO Eli Kalif - CFO Eric Hughes - Head, R&D & Chief Medical Officer Ran Meir - SVP, head of IR Conference Call Participants Ash Verma - UBS Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Omri Efroni - Oppenheimer Umer Raffat - Evercore Glen Santangelo - Jefferies Chris Schott - J.P. Morgan Yifeng...

CNBC Television

Jul 31, 2024

Teva Pharma CEO: Majority of momentum came from innovative b...

Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss how much of the company's momentum is around its generic obesity drug, the market's excitement around its GLP-1 drug, and much more.

Zacks Investment Research

Jul 31, 2024

Teva Pharmaceutical Industries (TEVA) Reports Q2 Earnings: W...

Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research

Jul 31, 2024

Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued R...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep